Amphista Therapeutics Unveils AMX-883 for Clinical Trials
Amphista Therapeutics, a pioneering force in the realm of drug discovery, has recently announced an exciting development. The company has nominated AMX-883 as its inaugural clinical candidate in the fight against acute myeloid leukaemia (AML). Utilizing the innovative Targeted Glue™ technology, AMX-883 functions by targeting BRD9, employing a unique mechanism distinct from existing treatments.
Mechanism and Potential of AMX-883
AMX-883 represents a significant advancement in targeted protein degradation. It operates through the recruitment of DCAF16 to induce BRD9 degradation, setting it apart from traditional methods that rely on cereblon or VHL-based approaches. This novel mechanism of action positions AMX-883 as a cutting-edge candidate that promises a multifaceted benefit for AML patients.
Impact of BRD9 in Acute Myeloid Leukaemia
Research supports that BRD9 plays a crucial role in the pathology of AML, suggesting that its degradation could lead to enhanced differentiation of myeloid cells. In preclinical studies, AMX-883 has shown remarkable potency and selectivity, achieving nearly complete degradation of BRD9 within hours while preserving efficacy against other proteins.
As AML is known for its aggressive nature, the need for innovative treatments has never been more pressing. The introduction of AMX-883 aims to address this gap, potentially transforming the therapeutic landscape for many patients.
Funding and Future Trials
With the nomination of AMX-883, Amphista Therapeutics unlocks the third tranche of its Series B financing. This financial support is essential for paving the way towards initiating clinical trials anticipated in the second half of 2026. The company demonstrates a clear commitment to advancing its pipeline of next-generation therapeutic options.
Statements from Leadership
Martin Pass, Amphista's Chief Development Officer, emphasizes the significance of this nomination, noting that AMX-883 represents a critical milestone not just for the company, but for the entire field of targeted protein degradation. He anticipates that AMX-883 could significantly impact AML treatment, addressing the urgent needs of a broader patient population.
Antony Mattessich, the company's Chief Executive Officer, further added that the Eclipsys® platform has positioned Amphista at the forefront of drug discovery, offering the ability to deliver advanced therapeutics surpassing previous limitations seen with conventional agents.
About Acute Myeloid Leukaemia (AML)
Acute myeloid leukaemia stands as one of the most formidable blood cancers, notorious for low survival rates among diagnosed individuals. Current treatment options, while available, often fall short of expectations due to biological complexity and varied genetic profiles among patients. With AMX-883, there's hope for a new treatment paradigm that transcends existing limitations and offers broader efficacy.
Through breaking down the differentiation barriers in AML, therapies like AMX-883 could pave the way for better patient outcomes, addressing both effectiveness and accessibility.
About Amphista Therapeutics
Amphista Therapeutics is dedicated to enhancing patient lives through innovative approaches in targeted protein degradation. The company strategically leverages its Eclipsys® platform to pioneer therapeutics that promise first- and/or best-in-class properties. Since its inception, Amphista has aligned with esteemed partners in the investment sector, propelling its mission forward.
For additional inquiries, please feel free to contact:
Amphista Therapeutics
John Goodall
Email: Info@amphista.com
ICR Healthcare
Amber Fennell, Namrata Taak
Emily Johnson
Email: Amphista@icrhealthcare.com
Tel: +44 (0)20 3709 5813
Frequently Asked Questions
What is AMX-883?
AMX-883 is a novel, orally available Targeted Glue™ degrader of BRD9, aimed at treating acute myeloid leukaemia.
How does AMX-883 work?
AMX-883 utilizes a unique mechanism that induces degradation of BRD9 by recruiting DCAF16, differing from traditional PROTACs.
What is the significance of BRD9 in AML?
BRD9 has a crucial role in the development of AML, making its degradation a promising target for treatment interventions.
When will clinical trials for AMX-883 begin?
Amphista Therapeutics plans to commence clinical trials for AMX-883 in the second half of 2026.
How does Amphista Therapeutics contribute to cancer treatment?
Amphista Therapeutics focuses on creating advanced targeted protein degradation medicines that offer new possibilities in the treatment of cancer and other severe diseases.
